Researchers from North Carolina State University, Institut Langevin and Paris-Descartes University have conducted a proof-of-concept study that raises the possibility of using ultrasound techniques to detect cervical stiffness changes that indicate an increased risk of preterm labour in pregnant women. While additional work needs to be done, it may ultimately give doctors a new tool for determining when to provide treatment that can prevent preterm birth.
Premature births can mean low birthweights and other medical problems for newborns, but there are steps that doctors can take to reduce the chances of premature birth if early warning signs are detected. One of those early symptoms is a softening of the cervix. Traditionally, this stiffness is assessed by manually palpating the cervix.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:12Proof-Of-Concept study shows potential for using ultrasound to detect early signs of preterm labour
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
MRI-scannerMagnetic resonance imaging (MRI) scanners have been used since the 1980s to take detailed images inside the body
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:12MRI scanners can steer tumour busting viruses to specific target sites within the body
In the future, TAVIs can only be carried out in German hospitals with cardiac surgery departments and cardiac wards, as decided by the German Government
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:11Restrictive ruling on cardiac procedure
An international research collaboration led by Massachusetts General Hospital (MGH) investigators has identified the first gene in which mutations cause the common form of mitral valve prolapse (MVP), a heart valve disorder that affects almost 2.5 percent of the population. The research team reports finding mutations in a gene called DCHS1 in affected members of three families in which MVP is inherited.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:11First gene that causes mitral valve prolapse identified
The atrial fibrillation patient website AFib Matters has been launched in Italian and Spanish by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC). Italian version: www.fibrillazioneatriale.org Spanish version: www.fibrilacion-auricular.org
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:11Atrial fibrillation patient website launched in Italian and Spanish
Vygon, the specialist single-use medical devices group, has acquired Perouse Medical, a French company which designs, manufactures and markets cardiovascular medical devices (stents, vascular grafts and patches, radial compression and inflation systems, hemostasic valves, angiographic syringes as well as consumables for contrast media injectors for CT scanners and MRI, etc.) and long-term vascular access devices (implantable ports, PICCs, Huber needles, catheter maintenance dressings, etc.). Established in 1984, Perouse Medical generated a turnover of
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:11The Vygon Group buys Perouse Medical
The Edison Awards, celebrating 28 years of honoring the best in innovation and excellence in the development of new products and services, announced today that the Barco Coronis Uniti
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:10Barco Coronis Uniti? named a 2015 Silver Edison Award winner
SCHILLER has teamed up with medsim specialists EPICARDIO to offer a market-leading simulation-based ECG e-learning program to its customers. Responding to requests from its customers to provide innovative training techniques to complement its medical technology solutions, SCHILLER has worked with the UK-based company to bring them a cutting-edge customized e-training package. This fully interactive
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:10Education technology partnership between SCHILLER and EPICARDIO
About 50% of patients with Parkinson’s disease (PD) experience freezing of gait (FOG), an inability to move forward while walking. This can affect not only mobility but also balance. In a new study, researchers report that repetitive transcranial magnetic stimulation (rTMS) can reduce FOG and improve other motor skills in PD patients.
In a study conducted by researchers at the Sungkyunkwan University School of Medicine, Seoul, Korea, 17 PD patients experiencing FOG were treated with either real or sham high-frequency rTMS in five sessions over a one-week period. After a two-week interval, the patients in both groups were switched to the other treatment. Patients were assessed at three times: at the beginning of the study before stimulation began (pre-rTMS at day 1), immediately after the intervention (post-rTMS at day 5), and one week after cessation of the intervention (follow up at day 12). After switching, the three assessments were repeated. All medications were kept constant throughout the study and all interventions were performed at the same time of day. Both the researchers and the patients were not informed whether real or sham treatment was being administered.
‘This study demonstrated that five cumulative sessions a week of 10 Hz high-frequency rTMS was likely to alleviate FOG in patients with PD, and the effect continued for a week. Similar results were found in the motor and the gait function,’ explained lead investigator Yun-Hee Kim, MD, PhD, Professor in the Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ‘This study provides evidence that the cumulative high-frequency rTMS is a good candidate as an add-on therapy for FOG in PD.’
The location in each patient’s scalp for optimal stimulation of the anterior tibialis muscle (the front of lower leg) was mapped by stimulating the muscle and moving a pickup coil over the scalp to find the greatest response. This position was then used for each treatment.
A magnetic stimulator was placed and 20 pulses of 10 Hz rTMS were delivered to the target motor cortex areas of the dominant hemisphere. Each pulse lasted five seconds, with 55-second intervals between pulses, delivering 1,000 pulses in 20 minutes. Sham stimulation was conducted with a coil held at a 90 degree position in order to ensure that the magnetic field did not stimulate the motor cortex.
Patients were evaluated after treatments using the FOG-Q, a self-assessment scale for evaluating FOG symptoms in Parkinson’s syndrome. In addition, participants were instructed to walk to a target (traffic cone) one meter behind them, turn around, and then return, as part of a Timed-Up-and-Go (TUG) task during a modified Standing-Start 180 degree Turn Test (SS-180). The TUG task was repeated twice in each direction, and the entire process was video recorded to quantify FOG.
When patients underwent real treatment, the FOG-Q and TUG at post-rTMS significantly improved compared with pre-rTMS and these results continued into the follow up period. However, there were no significant changes in FOG-Q or TUG at post-rTMS and follow-up in patients when experiencing the sham treatment.
EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:10Magnetic stimulation effective in helping Parkinson’s patients walk
Engineers at the University of California, San Diego, have developed a mouth guard that can monitor health markers, such as lactate, cortisol and uric acid, in saliva and transmit the information wirelessly to a smart phone, laptop or tablet.
The technology, which is at a proof-of-concept stage, could be used to monitor patients continuously without invasive procedures, as well as to monitor athletes
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:562020-08-26 14:39:10Mouth guard monitors health markers, transmits information wirelessly to smart phone
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.